What does HAINAPHARMA do?

HAINAPHARMA is a pharmacy in Aiseau-Presles. Private Limited, started on 31 March 1989, 2 establishments.

What is the address of HAINAPHARMA?

The registered office of HAINAPHARMA is located at Place Communale(PR) 6, 6250 Aiseau-Presles.

Is HAINAPHARMA still active?

Yes. According to the CBE (30 October 2026) HAINAPHARMA is active, legal situation “Normale toestand”, started on 31 March 1989.

Is HAINAPHARMA registered on Peppol?

Yes, HAINAPHARMA is registered on the Peppol network with ID 0208:0437182661.

What is the enterprise number of HAINAPHARMA?

The enterprise number of HAINAPHARMA is BE0437182661.

When was HAINAPHARMA founded?

HAINAPHARMA was founded on 31 March 1989.

Who are the directors of HAINAPHARMA?

According to the 2025 annual accounts, the directors of HAINAPHARMA are: Marie-Cécile BAJART, Edouard DUBOIS.

Is HAINAPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 31 March 1989; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account; 2 establishments in the CBE.

How much profit did HAINAPHARMA make in 2025?

HAINAPHARMA posted a profit after taxes of € 195,381 in financial year 2025.

What is the revenue of HAINAPHARMA?

As a small company, HAINAPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 878,061.

How much does an employee at HAINAPHARMA earn?

The average wage cost per full-time employee at HAINAPHARMA was € 47,800 in 2025: staff costs of € 445,004 for 9.3 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does HAINAPHARMA have?

According to the 2025 annual accounts, HAINAPHARMA has 9.3 full-time equivalents (FTE).

HAINAPHARMA (Private Limited) - Aiseau-Presles

Dossier HAINAPHARMA, printed on 30 October 2026 from databakkes.be/en/0437182661/hainapharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

HAINAPHARMA from Aiseau-Presles, company number BE0437182661, closed financial year 2025 with a result of € 195,381 after tax. For that financial year HAINAPHARMA recorded a gross margin of € 878,061 and equity of € 2 million. Compared with financial year 2024, the result moved from € 69,262 to € 195,381. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 26, 2026.

What it is worth Growing

€ 2 million

▲ 11% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 195,381

▲ 182% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 236,470

▲ 10% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 2 million.

People and assets in 2025

Full-time equivalents

9.3

▼ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 445,004

▲ 2% vs 2024

€ 47,800 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 17,638

▼ 35% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 583,464

▼ 21% vs 2024

€ 151,135 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 373,349

▲ 17% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 91,439

▼ 7% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 775,995 Gross margin 2022: € 775,995 First fiscal year in the series	€ 869,566 Gross margin 2023: € 869,566 ▲ 12% vs 2022 (€ 775,995) Favourable step	€ 924,984 Gross margin 2024: € 924,984 ▲ 6% vs 2023 (€ 869,566) Favourable step	€ 878,061 Gross margin 2025: € 878,061 ▼ 5% vs 2024 (€ 924,984) Unfavourable step	▼ 5%
Profit after taxes	€ 112,754 Profit after taxes 2022: € 112,754 First fiscal year in the series	€ 149,239 Profit after taxes 2023: € 149,239 ▲ 32% vs 2022 (€ 112,754) Favourable step	€ 69,262 Profit after taxes 2024: € 69,262 ▼ 54% vs 2023 (€ 149,239) Unfavourable step	€ 195,381 Profit after taxes 2025: € 195,381 ▲ 182% vs 2024 (€ 69,262) Favourable step	▲ 182%
Equity	€ 1,602,068 Equity 2022: € 1,602,068 First fiscal year in the series	€ 1,751,307 Equity 2023: € 1,751,307 ▲ 9% vs 2022 (€ 1,602,068) Favourable step	€ 1,820,569 Equity 2024: € 1,820,569 ▲ 4% vs 2023 (€ 1,751,307) Favourable step	€ 2,015,950 Equity 2025: € 2,015,950 ▲ 11% vs 2024 (€ 1,820,569) Favourable step	▲ 11%
Total debts	€ 2,398,546 Total debts 2022: € 2,398,546 First fiscal year in the series	€ 2,205,432 Total debts 2023: € 2,205,432 ▼ 8% vs 2022 (€ 2,398,546) Favourable step	€ 1,997,208 Total debts 2024: € 1,997,208 ▼ 9% vs 2023 (€ 2,205,432) Favourable step	€ 2,010,741 Total debts 2025: € 2,010,741 ▲ 1% vs 2024 (€ 1,997,208) Unfavourable step	▲ 1%
Cash	€ 146,199 Cash 2022: € 146,199 First fiscal year in the series	€ 322,306 Cash 2023: € 322,306 ▲ 120% vs 2022 (€ 146,199) Favourable step	€ 215,616 Cash 2024: € 215,616 ▼ 33% vs 2023 (€ 322,306) Unfavourable step	€ 236,470 Cash 2025: € 236,470 ▲ 10% vs 2024 (€ 215,616) Favourable step	▲ 10%
Land & buildings	€ 2,130,354 Land & buildings 2022: € 2,130,354 First fiscal year in the series	€ 2,033,889 Land & buildings 2023: € 2,033,889 ▼ 5% vs 2022 (€ 2,130,354) Unchanged	€ 1,941,227 Land & buildings 2024: € 1,941,227 ▼ 5% vs 2023 (€ 2,033,889) Unchanged	€ 1,898,703 Land & buildings 2025: € 1,898,703 ▼ 2% vs 2024 (€ 1,941,227) Unchanged	▼ 2%
Retained profit	€ 1,583,468 Retained profit 2022: € 1,583,468 First fiscal year in the series	€ 1,732,707 Retained profit 2023: € 1,732,707 ▲ 9% vs 2022 (€ 1,583,468) Favourable step	€ 1,801,969 Retained profit 2024: € 1,801,969 ▲ 4% vs 2023 (€ 1,732,707) Favourable step	€ 1,997,350 Retained profit 2025: € 1,997,350 ▲ 11% vs 2024 (€ 1,801,969) Favourable step	▲ 11%
Bank debt	€ 1,210,729 Bank debt 2022: € 1,210,729 First fiscal year in the series	€ 961,609 Bank debt 2023: € 961,609 ▼ 21% vs 2022 (€ 1,210,729) Favourable step	€ 738,256 Bank debt 2024: € 738,256 ▼ 23% vs 2023 (€ 961,609) Favourable step	€ 583,464 Bank debt 2025: € 583,464 ▼ 21% vs 2024 (€ 738,256) Favourable step	▼ 21%
Balance sheet total	€ 4,000,614 Balance sheet total 2022: € 4,000,614 First fiscal year in the series	€ 3,956,738 Balance sheet total 2023: € 3,956,738 ▼ 1% vs 2022 (€ 4,000,614) Unchanged	€ 3,817,777 Balance sheet total 2024: € 3,817,777 ▼ 4% vs 2023 (€ 3,956,738) Unchanged	€ 4,026,691 Balance sheet total 2025: € 4,026,691 ▲ 5% vs 2024 (€ 3,817,777) Unchanged	▲ 5%
Employees (FTE)	9.5 Employees (FTE) 2022: 9.5 First fiscal year in the series	9.5 Employees (FTE) 2023: 9.5 Unchanged (9.5) Unchanged	9.4 Employees (FTE) 2024: 9.4 ▼ 0.1 vs 2023 (9.5) Unchanged	9.3 Employees (FTE) 2025: 9.3 ▼ 0.1 vs 2024 (9.4) Unchanged	▼ 0.1

Key figures of HAINAPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to HAINAPHARMA?

What happened at HAINAPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 26, 2026 New annual accounts for financial year 2025: profit of € 195,381 (▲ 182% vs 2024). filed late Source: NBB ↗
Apr 7, 2006 New establishment in Fosses-la-Ville. KBO
1998 Marie-Cécile BAJART became a director. NBB
1998 Edouard DUBOIS became a director. NBB
Apr 19, 1989 New establishment in Aiseau-Presles. KBO
Mar 31, 1989 Start of the company according to the CBE. KBO

In short

From € 112,754 profit in 2022 to € 195,381 profit in 2025.

Paid € 181,877 in corporate taxes since 2022.

Best year ever: 2025, with € 195,381 profit.

On average € 94,400 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

ESPHAR 49.3%

The stake of ESPHAR comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

HAINAPHARMA

Behind HAINAPHARMA are Marie-Cécile BAJART and Edouard DUBOIS. The shares are held by ESPHAR (49.3%).

Directors

According to the 2025 annual accounts

Marie-Cécile BAJART

Manager

since 1998

Edouard DUBOIS

Manager

Also active at: ESPHAR

since 1998

Shareholders

ESPHAR

49.3%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Place Communale(PR) 6

6250 Aiseau-Presles

2.043.062.104

Rue de l'S(PR) 2 box A

6250 Aiseau-Presles

Active since 19 April 1989

2.152.792.066

Chaussée de Charleroi 352

5070 Fosses-la-Ville

Active since 7 April 2006

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

PRESLES PHYSIO

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0437.182.661

VAT number

BE 0437.182.661

Registered office

Place Communale(PR) 6, 6250 Aiseau-Presles

Names & denominations

HAINAPHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

31 March 1989

Peppol

Active · Active since 13 Oct 2025

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

HAINAPHARMA

Financials

What happened to HAINAPHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions